Trial will evaluate efficacy of anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev
News
Gilead’s CAR T-cell therapy recommended for use across the NHS
Treatment involves adult patients with relapsed or refractory diffuse large B-cell lymphoma
Storm reveals STC-15 data for patients with acute myeloid leukaemia
Data shows that STC-15 exhibits efficacy as a single agent and in combination with venetoclax
Evgen completes three cohorts for SFX-01
New enteric-coated tablet formulation will now replace the previous prototype capsule
First-in-human implants for Amber Therapeutics’ bioelectrical therapy
Amber-UI presents a significant opportunity to treat urge and mixed urinary incontinence
Memo Therapeutics reveals positive AntiBKV data
Therapy involves renal transplant patients requiring treatment of BK polyomavirus infection
First patients enrolled for Priothera’s mocravimod trial
Treatment is a maintenance therapy for certain patients with acute myeloid leukaemia
OxSonics trial produces positive SonoTran data
During the research SonoTran is being evaluated in patients with metastatic colorectal cancer
NICE recommends Takeda’s Ninlaro triplet regimen
Therapy involves patients living with relapsed or refractory multiple myeloma
NICE recommends PTC Therapeutics’ Translarna reimbursement
The NICE recommendation followed data from clinical trials and real-world evidence
Amvuttra recommended by NICE for amyloidosis
Therapy is among the first to receive a positive draft recommendation under streamlined pilot process
NeoPhore gains additional financing for discovery pipeline
The new funding package will be used to progress NeoPhore’s expanding pipeline of therapies
NHS Confederation very concerned by latest industrial action
Unrelenting pressure caused by strikes, flu and COVID-19 may be keeping NHS in vicious cycle
Scottish Medicines Consortium recommends Merck’s Tepmetko
Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients
Stada and Xbrane receive approval for Ximluci
Biosimilar gains MHRA marketing authorisation for use throughout Britain
